Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Oral Bioavailability of 400 mg BI 44847 as Suspension Compared to 400 mg BI 44847 as Tablet and the Influence of Food (Standardised High Fat Breakfast) on the Tablet in a Single Dose, Open-label, Randomised Three-way Crossover Trial and Relative Oral Bioavailability of 40 mg BI 44847 as Solution Compared to 40 mg BI 44847 as Tablet in Healthy Male Volunteers in a Single Dose, Open-label, Randomised Two-way Crossover Trial

NCT02211937 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02211937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02211937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Oral Bioavailability of 400 mg BI 44847 as Suspension Compared to 400 mg BI 44847 as Tablet and the Influence of Food (Standardised High Fat Breakfast) on the Tablet in a Single Dose, Open-label, Randomised Three-way Crossover Trial and Relative Oral Bioavailability of 40 mg BI 44847 as Solution Compared to 40 mg BI 44847 as Tablet in Healthy Male Volunteers in a Single Dose, Open-label, Randomised Two-way Crossover Trial
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2007
Completion date
Not reported
Enrollment
25 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy